EPIX Similar Chart Price Prediction
The price of EPIX is predicted to go up 5.65%, based on the high correlation periods with RBBN. The similarity of these two price pattern on the periods is 90.58%.
EPIX
RBBN
Up: 5.65%Similarity: 90.58%
EPIX Revenue Forecast
EPIX EPS Forecast
EPIX FAQs
What is EPIX eps forecast for next quarter？
EPIX Analyst's Forecast
Joseph Catanzaro
Piper Sandler
Buy → Hold
2024-11-04
Price Target
$15 → $2
Upside
+22.7%
Piper Sandler analyst Joseph Catanzaro downgraded Essa Pharma to Neutral from Overweight with a price target of $2, down from $15. The company announced the discontinuation of masofaniten's randomized Phase II trial in combination with enzalutamide in anti-androgen naive metastatic castration-resistant prostate cancer following an interim analysis that suggested the trial was unlikely to meet the primary endpoint, the analyst tells investors in a research note. With all other masofaniten studies are also being discontinued with the company evaluating all potential strategic options, Piper removed all value for masofaniten and downgraded the shares.
Leland Gershell
Oppenheimer
Buy → Hold
2024-11-04
Price Target
n/a
Downside
0%
Soumit Roy
Jones Trading
Strong Buy → Hold
2024-11-01
Price Target
n/a
Downside
0%
